New York, USA - March 2, 2026 - By integrating proprietary Afuco™ technology and site-specific mutagenesis, Creative Biolabs is addressing the industry-wide challenge of enhancing the immunological potency of biobetters.
Precision Engineering for Enhanced Effector Functions
In the evolving landscape of immunotherapy, the therapeutic success of an antibody often depends on its ability to trigger the immune system. Creative Biolabs provides comprehensive ADCC enhancement technology designed to significantly boost antibody-dependent cellular cytotoxicity. The core of this platform is the Afuco™ technology, which utilizes glycoengineering to produce afucosylated antibodies. By removing fucose residues from the Fc glycan, the platform increases the binding affinity to FcγRIIIa on Natural Killer (NK) cells by up to 50-fold, leading to superior tumor cell lysis.
Complementing this, the company's CDC enhancement technology focuses on complement-dependent cytotoxicity. Through precise amino acid substitutions in the Fc region—such as the EFTAE modification—Creative Biolabs increases C1q binding and hexamer formation, accelerating the complement cascade even in cells with low antigen density.
Scaling the Pipeline: ADCC and CDC Enhanced Biobetters
Beyond platform services, Creative Biolabs offers a robust catalog of ADCC-enhanced biobetters and CDC-enhanced biobetters. These "best-in-class" molecules are optimized versions of established monoclonal antibodies (mAbs) targeting HER2, EGFR, and CD20, providing researchers with high-potency benchmarks for comparative studies and clinical development.
"Our goal is to transcend the limitations of conventional monoclonal antibodies," stated a Senior Scientist at Creative Biolabs. "By fine-tuning the Fc-mediated effector functions, we are not just increasing kill rates in vitro; we are providing the foundation for therapies that can overcome drug resistance in patients with refractory tumors."
Technical Insights: Addressing Industry Challenges (FAQ Analysis)
To better support the global research community, Creative Biolabs has integrated technical resolutions to common engineering hurdles into their workflow:
Balancing Half-life and Potency: A frequent concern in Fc engineering is whether enhancing ADCC/CDC negatively impacts the antibody's half-life. Creative Biolabs utilizes dual-modification strategies that enhance effector function while preserving or extending neonatal Fc receptor (FcRn) binding.
Immunogenicity Risks: The platforms prioritize "human-like" glycosylation patterns and minimized mutation profiles to ensure that enhanced biobetters maintain a low immunogenicity profile, a critical factor for successful clinical transition.
About Creative Biolabs
With decades of experience in the biotechnology sector, Creative Biolabs supports a wide range of therapeutic areas, including oncology, immunology, and infectious diseases, through innovative platforms for antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered therapeutics.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://adcc.creative-biolabs.com
